Skip to content

Study · Randomized controlled trial · n = 93 · 1997

3 results

Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis.

Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL

Fertility and sterility1 Nov 1997Cited by 87 (Europe PMC)

PMID9389816 (opens in a new tab)DOI10.1016/s0015-0282(97)00360-9 (opens in a new tab)PepBankPUB-09389816
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After endometriosis surgery, alternative therapy was required by 15 of 49 nafarelin recipients (31%) versus 25 of 44 placebo recipients (57%).

    In plain wordsFewer women required alternative therapy with nafarelin than placebo after endometriosis surgery.

    Peptide
    Nafarelin
    Outcome
    DecreaseRequirement for alternative therapy
    Study

    n = 93

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · 6 monthsAs given in this study (human).

    Measurements

    Alternative therapy recipients
    15 patients
    nafarelin
    Alternative therapy requirement
    31%
    nafarelin
    Alternative therapy recipients
    25 patients
    placebo
    Alternative therapy requirement
    57%
    placebo

    Source sentences

    Summary
    Fifteen (31%) of 49 nafarelin-treated patients required alternative therapy, compared with 25 (57%) of 44 placebo-treated patients.
    2 context sentences
    Summary · context
    One hundred nine women aged 18-47 with laparoscopically proven endometriosis and pelvic pain who had undergone reductive laparoscopic surgery for endometriosis.
    Summary · context
    Patients were randomized to receive either the GnRH-a nafarelin (200 micrograms twice daily) or placebo for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After endometriosis surgery, median time to alternative treatment was >24 months with nafarelin versus 11.7 months with placebo.

    In plain wordsAfter surgery, nafarelin delayed alternative treatment compared with placebo.

    Peptide
    Nafarelin
    Outcome
    IncreaseTime to alternative treatment
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · 6 monthsAs given in this study (human).

    Measurements

    Median time to alternative treatment
    > 24 months
    nafarelin
    Median time to alternative treatment
    11.7 months
    placebo

    Source sentences

    Summary
    The median time to initiation of alternative treatment was > 24 months in the nafarelin group versus 11.7 months in the placebo group.
    2 context sentences
    Summary · context
    One hundred nine women aged 18-47 with laparoscopically proven endometriosis and pelvic pain who had undergone reductive laparoscopic surgery for endometriosis.
    Summary · context
    Patients were randomized to receive either the GnRH-a nafarelin (200 micrograms twice daily) or placebo for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    After endometriosis surgery, physician summary ratings improved significantly from baseline with nafarelin after 6 months, while placebo ratings did not.

    In plain wordsPhysician ratings improved from baseline with nafarelin after 6 months, while placebo ratings did not change significantly.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedPhysician-rated improvement at 6 months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Physician summary ratings showed significant improvement in the nafarelin group and no significant changes in the placebo group after 6 months of treatment.
    2 context sentences
    Summary · context
    One hundred nine women aged 18-47 with laparoscopically proven endometriosis and pelvic pain who had undergone reductive laparoscopic surgery for endometriosis.
    Summary · context
    Patients were randomized to receive either the GnRH-a nafarelin (200 micrograms twice daily) or placebo for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.